Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immun…
USD104.00+1.06%vs prev. close
Performance
1W
+6.54%
1M
+27.92%
3M
+1.04%
1Y
+339.22%
YTD
+214.13%
Valuation
P/E
—
EPS TTM
-2.52
Dividend yield
—
Size and risk
Market cap
$9.9B
Beta
3.23
Price history
SYRE price
USD
Total returnEventsVs index
Loading…
Next earnings
Report date
EPS estimate
Revenue estimate
Peer comparison
Spyre Therapeutics
SYRE
Biotechnology
Mkt cap (USD bn)
9.9
P/E
—
Div yld
—
1W
+6.5%
1M
+27.9%
3M
+1.0%
6M
+36.0%
1Y
+339.2%
YTD
+214.1%
Company
Ticker
Industry
Mkt cap (USD bn)
P/E
Div yld
1W
1M
3M
6M
1Y
YTD
Spyre Therapeutics
SYRE
Biotechnology
9.9
—
—
+6.5%
+27.9%
+1.0%
+36.0%
+339.2%
+214.1%
Subscribe to Equity Analytics to compare SYRE with its closest peers
Sector-matched peer set with side-by-side valuation, dividend and performance over every window.